IQ-AI Soars As StoneChecker Software Gets US FDA Sign-Off

IQ-AI Ltd said it has received the regulatory green light in America for its StoneChecker software, which is used to assess kidney stones.

Imaging Biometrics, the company’s Milwaukee-based subsidiary, was granted “clearance to market” by the US Food & Drug Administration. The company said it would issue an update outlining the scale of the opportunity along with its product roll-out plans in the next few days. – Proactive Investors